Notice of Thallion Pharmaceuticals 2009 Third Quarter Conference Call
* Reuters is not responsible for the content in this press release.
MONTREAL, QUEBEC, Oct 08 (MARKET WIRE) --
Thallion Pharmaceuticals Inc. (TSX: TLN) will release its 2009 third
quarter financial results on Wednesday, October 14, 2009 after 4:00 PM
Eastern Time. The Company will subsequently hold a conference call on
Wednesday, October 14, 2009 at 4:30 PM Eastern Time hosted by Mr. Lloyd
M. Segal, Chief Executive Officer and Mr. Michael Singer, Chief Financial
Officer. A question and answer session will follow the corporate update.
CONFERENCE CALL DETAILS
DATE: October 14, 2009
TIME: 4:30 PM Eastern Time
DIAL IN NUMBER: 416-644-3423 or 1-800-589-8577
TAPED REPLAY: 416-640-1917 or 1- 877-289-8525
REFERENCE NUMBER: 4170511#
A live audio webcast of the conference call will be available by
visiting the Company's website at www.thallion.com. Please connect at
least 15 minutes prior to the conference call to ensure adequate time for
any software download that may be needed to hear the webcast.
About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company
developing pharmaceutical products in the areas of oncology and
infectious disease. The Company's clinical programs include TLN-4601 and
Shigamabs(R). TLN-4601 is a novel anti-cancer therapy targeting the
RAS-MAPK pathway which is actively enrolling patients at multiple sites
in Canada and the United States in a Phase II trial for brain cancer.
Shigamabs(R) is a dual antibody product for the treatment of Shigatoxin
producing E. coli bacterial infections which is ready to begin a Phase
II/III clinical program upon the completion of a development partnership.
Additional information about Thallion can be obtained at www.thallion.com.
Forward-Looking Statements
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect Thallion's current expectation and
assumptions, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated.
These forward-looking statements involve risks and uncertainties
including, but not limited to, the obtaining of regulatory approvals and
consents, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate alliances,
the impact of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process and other risks
detailed from time-to-time in Thallion's ongoing filings with the
Canadian securities regulatory authorities which filings can be found at
www.sedar.com. Given these risks and uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. Thallion
undertakes no obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or
otherwise, except as required by applicable Canadian securities laws.
Contacts:
Thallion Pharmaceuticals Inc.
Michael Singer
Chief Financial Officer
514-940-3600
514-228-3622 (FAX)
info@thallion.com
www.thallion.com
The Equicom Group Inc.
Ross Marshall
Investor Relations
416-815-0700 (Ext. 238)
416-815-0080 (FAX)
rmarshall@equicomgroup.com
Copyright 2009, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters